Newsletters

[Cell Death Discovery] Through pulse selection of the parental cells, researchers established docetaxel- and cabazitaxel-resistant CRPC cell models and integrated different omic approaches, including transcriptomics and proteomics, to determine the molecular signatures underlying taxane resistance.

[British Journal of Cancer] Scientists investigated how SUMOylation regulates EphB4 localisation, stability and function in prostate cancer (PCa). They reported that SUMOylation at K616 stabilizes EphB4, promotes MYC signaling, and PCa cell migration.

[Cell Death & Differentiation] Scientists elucidated the role of Wnt pathway activation in mediating resistance to androgen receptor (AR) signaling inhibition and identified a robust molecular signature for predicting treatment outcomes.

[Cancer Gene Therapy] Researchers utilized a tissue microarray and collected tissues from prostate cancer (PCa) patients to detect Wilms’ tumor 1-associating protein (WTAP) expression, and found that WTAP is upregulated in PCa.

[Cancer Research] Investigators performed a comprehensive analysis of cancerous and adjacent-benign cores from 24 patients with hormone therapy–naïve localized prostate cancer using single-cell RNA sequencing.

[Oncogene] Scientists found that knockdown of ALYREF reduces the proliferation, invasion and metastasis of prostate cancer. ALYREF promotes anoikis resistance in prostate cancer by positively regulating BPIP3 and thereby activating autophagy.

[Molecular Cancer Therapeutics] Researchers integrated transcriptomic, functional, and clinical analyses to identify mitochondrial regulators of PARP inhibitor resistance.

[EMBO Molecular Medicine] The authors highlight elevated circulating neutrophil levels as a biomarker of prostate cancer dissemination and show the potency of targeting neutrophil chemotaxis to reduce liver micrometastases.

[Acerand Therapeutics] Acerand Therapeutics announced updated results from its first-in-human Phase I/II study ACE-106-001 evaluating ACE-106 in patients with advanced solid tumors of the prostate and ovary.

[Oregon Health & Science University] An NIH award of $2.5 million, led by Dr. Luiz Bertassoni, will focus on how aggressive prostate cancers grow to the bone. Using lab-grown bone tissues, his team will investigate how physical forces in blood vessels and signals from nerves help tumor cells lodge in bone and become more aggressive.

[Advanced Science] Scientists revealed a novel phagocytosis-mediated, paracrine mechanism of enzalutamide resistance orchestrated by androgen receptor-positive tumor-associated macrophages.

[Biology Direct] The authors address the development, progression, diagnosis, therapy, and prognosis of prostate cancer, focusing on the mechanistic role of the miR-143/145 cluster.